• 四川大學華西醫(yī)院,內(nèi)分泌科,成都,610041;

引用本文： 李秀鈞,馬鳳海. 循證醫(yī)學在內(nèi)分泌臨床中的應(yīng)用. 中國循證醫(yī)學雜志, 2004, 04(7): 442-445. doi: 復(fù)制

1. ［1］UKPDS Study Group.Klein R,Klein BE,Moss SE.Relation of glycennic control to diabetic microvascular complications in diabetes melitus[J].Ann Intern Med,1996;124(1Pt2);90-96.
2. ［2］Lindstrom J,Louheranta A,Mannelin M,Rastas M,Salminen V,Eriksson J,Uusitupa M,Tuomilehto J; Finnish Diabetes Prevention Study Group.The Finnish Diabetes Prevention Study (DPS):Lifestyle Intervention and 3-Year Results on Diet and Physical Activity [J].Diabetes Care,2003,26（12）:3 230-3 236.
3. ［3］Tuomilehto J,Lindstrom J,Eriksson JG.Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects With Impaired Glucose Tolerance[J].N Engl J Med,2001,344(18):1 343-1 350.
4. ［4］Knowler WC,Barrett-Connor E,Fowler SE,Hamman RF,Lachin JM,Walker EA,Nathan DM; Diabetes Prevention Program Research Group.Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin Diabetes Prevention Program Research Group[J].N Engl J Med,2002,346（6）:393-403.
5. ［5］Pan XR,Li GW,Hu YH,Wang JX,Yang WY,An ZX,Hu ZX,Lin J,Xiao JZ,Cao HB,Liu PA,Jiang XG,Jiang YY,Wang JP,Zheng H,Zhang H,Bennett PH,Howard BV.Effects of Diet and Exercise in Preventing NIDDM in People with Impaired Glucose Tolerance.The Da Qing IGT and Diabetes Study [J].Diabetes Care,1997,20(4):537-544.
6. ［6］Chiasson JL,Josse RG,Gomis R,Hanefeld M,Karasik A,Laakso M; STOP-NIDDM Trail Research Group.Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial.Lancet,2002; 359(9 323):2 072-2 077.
7. ［7］Yang WY,Lin LX,Qi JW,Yu ZQ,Pei HC,He GF.Yang ZJ,Wang F,Li GW,Pan XR.The prevention effcect of acarbose and Metformin on the IGTpopulation from becoming diabetes mellitus:a 3-year multicentral prospective study.Chinese Journal of Endocrinology and Metubolism,2001;17(3):131-134.
8. 楊文英林麗香齊今吾等阿卡波糖和二甲雙胍對IGT人群糖尿病預(yù)防的效果--多中心3年前瞻性觀察.中華內(nèi)分泌代謝雜志,2001年,17(3):131-134.
9. ［8］Pan CY,Gao Y,Chen JW.Efficacy of Acarbose in Chinese Subjects With Impaired Glucose Tolerance.Diabetes Research and Clinical Practice,2003; 61:183-190.
10. ［9］Hansson 1.Zanchetti A,Carruthers SG,Dahlof B,Elmfeldt D,Julius S,Menard J,Rahn KH,Wedel H,Westerling S.Effect of Intensive Blood-Pressure Lowering and Acetylsalicylic Acid in Patients with Hypertension:Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial [J].Lancet,1998; 351(9118):1755-1762.
11. ［10］The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J].N Engl J Med,1993; 329(14):977-86.
12. ［11］ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major Outcomes in Moderately Hypercholesterolemic,Hypertensive Patients Randomized to Pravastatin Vs Usual Care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) [J].JAMA,2002; 288(23):2 998-3 007.
13. ［12］Hansson L,Iindholm LH,Niskanen L.Effect of ACE-I Compared with Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension.The Captopril Prevention Project (CAPPP) randomized trial.Lancet,1999; 353:611.
14. ［13］Abraham P,Avenell A,Watson WA,et al.Antithyroid Drug Regimen for Treating Graves’ Hyperthyroidism (Cochrane Review).The Cochrane Library,Issue 2,2004.
15. ［14］Feldt-Rasmussen U,Schleusener H,Carayon P.Meta-Analysis Evaluation of the Impact of Thyrotropin Receptor Antibodies on Long Term Remission After Medical Therapy of Graves’ Disease.J Clin Endocrinol Metab,1994; 78(1):98-102.
16. ［15］Palit TK,Miller CC 3rd,Miltenburg DM.The Efficacy of Thyroidectomy for Graves’ Disease:A Meta-Analysis.J Surg Res,2000; 90(2):161-165.
17. ［16］Peters AL,Davidson MB,Schriger DL,Hasselblad V.A Clinical Approach for the Diagnosis of Diabetes Mellitus:An Analysis Using Glycosylated Hemoglobin Levels[J].JAMA,1996; 276(15):1 246-1 252.
18. ［17］Vijan S,Hayward RA.Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus:Background Paper for the American College of Physicians [J].Ann Intern Med.,2004; 140(8):650-658.
19. ［18］Glucose Tolerance and Mortality:Comparison Of WHO and American Diabetes Association Diagnostic Criteria.The DECODE Study Group.European Diabetes Epidemiology Group.Diabetes Epidemiology:Collaborative Analysis of Diagnostic Criteria in Europe [J].Lancet,1999; 354(9 179):617-621.
20. ［19］DECODE Study Group,the European Diabetes Epidemiology Group.Glucose Tolerance and Cardiovascular Mortality:Comparison Of Fasting and 2-Hour Diagnostic Criteria[J].Arch Intern Med,2001; 161(3):397-405.
21. ［20］The DECODE Study Group.Is the Current Definition for Diabetes Relevant to Mortality Risk From All Causes and Cardiovascular and Noncardiovascular Diseases[J]? Diabetes Care,2003; 26（3）:637-687.
22. ［21］Surks MI,Ortiz E,Daniels GH,Sawin CT,Col NF Cobin RH,Franklyn JA,Hershman JM,Burman KD,Denke MA,Gorman C,Cooper RS,Weissman N.Subclinical Thyroid Disease:Scientific Review and Guidelines for Diagnosis and Management.[J].JAMA,2004,291:228-238.
  1. 1. ［1］UKPDS Study Group.Klein R,Klein BE,Moss SE.Relation of glycennic control to diabetic microvascular complications in diabetes melitus[J].Ann Intern Med,1996;124(1Pt2);90-96.
  2. 2. ［2］Lindstrom J,Louheranta A,Mannelin M,Rastas M,Salminen V,Eriksson J,Uusitupa M,Tuomilehto J; Finnish Diabetes Prevention Study Group.The Finnish Diabetes Prevention Study (DPS):Lifestyle Intervention and 3-Year Results on Diet and Physical Activity [J].Diabetes Care,2003,26（12）:3 230-3 236.
  3. 3. ［3］Tuomilehto J,Lindstrom J,Eriksson JG.Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects With Impaired Glucose Tolerance[J].N Engl J Med,2001,344(18):1 343-1 350.
  4. 4. ［4］Knowler WC,Barrett-Connor E,Fowler SE,Hamman RF,Lachin JM,Walker EA,Nathan DM; Diabetes Prevention Program Research Group.Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin Diabetes Prevention Program Research Group[J].N Engl J Med,2002,346（6）:393-403.
  5. 5. ［5］Pan XR,Li GW,Hu YH,Wang JX,Yang WY,An ZX,Hu ZX,Lin J,Xiao JZ,Cao HB,Liu PA,Jiang XG,Jiang YY,Wang JP,Zheng H,Zhang H,Bennett PH,Howard BV.Effects of Diet and Exercise in Preventing NIDDM in People with Impaired Glucose Tolerance.The Da Qing IGT and Diabetes Study [J].Diabetes Care,1997,20(4):537-544.
  6. 6. ［6］Chiasson JL,Josse RG,Gomis R,Hanefeld M,Karasik A,Laakso M; STOP-NIDDM Trail Research Group.Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomised trial.Lancet,2002; 359(9 323):2 072-2 077.
  7. 7. ［7］Yang WY,Lin LX,Qi JW,Yu ZQ,Pei HC,He GF.Yang ZJ,Wang F,Li GW,Pan XR.The prevention effcect of acarbose and Metformin on the IGTpopulation from becoming diabetes mellitus:a 3-year multicentral prospective study.Chinese Journal of Endocrinology and Metubolism,2001;17(3):131-134.
  8. 8. 楊文英林麗香齊今吾等阿卡波糖和二甲雙胍對IGT人群糖尿病預(yù)防的效果--多中心3年前瞻性觀察.中華內(nèi)分泌代謝雜志,2001年,17(3):131-134.
  9. 9. ［8］Pan CY,Gao Y,Chen JW.Efficacy of Acarbose in Chinese Subjects With Impaired Glucose Tolerance.Diabetes Research and Clinical Practice,2003; 61:183-190.
  10. 10. ［9］Hansson 1.Zanchetti A,Carruthers SG,Dahlof B,Elmfeldt D,Julius S,Menard J,Rahn KH,Wedel H,Westerling S.Effect of Intensive Blood-Pressure Lowering and Acetylsalicylic Acid in Patients with Hypertension:Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial [J].Lancet,1998; 351(9118):1755-1762.
  11. 11. ［10］The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J].N Engl J Med,1993; 329(14):977-86.
  12. 12. ［11］ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major Outcomes in Moderately Hypercholesterolemic,Hypertensive Patients Randomized to Pravastatin Vs Usual Care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) [J].JAMA,2002; 288(23):2 998-3 007.
  13. 13. ［12］Hansson L,Iindholm LH,Niskanen L.Effect of ACE-I Compared with Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension.The Captopril Prevention Project (CAPPP) randomized trial.Lancet,1999; 353:611.
  14. 14. ［13］Abraham P,Avenell A,Watson WA,et al.Antithyroid Drug Regimen for Treating Graves’ Hyperthyroidism (Cochrane Review).The Cochrane Library,Issue 2,2004.
  15. 15. ［14］Feldt-Rasmussen U,Schleusener H,Carayon P.Meta-Analysis Evaluation of the Impact of Thyrotropin Receptor Antibodies on Long Term Remission After Medical Therapy of Graves’ Disease.J Clin Endocrinol Metab,1994; 78(1):98-102.
  16. 16. ［15］Palit TK,Miller CC 3rd,Miltenburg DM.The Efficacy of Thyroidectomy for Graves’ Disease:A Meta-Analysis.J Surg Res,2000; 90(2):161-165.
  17. 17. ［16］Peters AL,Davidson MB,Schriger DL,Hasselblad V.A Clinical Approach for the Diagnosis of Diabetes Mellitus:An Analysis Using Glycosylated Hemoglobin Levels[J].JAMA,1996; 276(15):1 246-1 252.
  18. 18. ［17］Vijan S,Hayward RA.Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus:Background Paper for the American College of Physicians [J].Ann Intern Med.,2004; 140(8):650-658.
  19. 19. ［18］Glucose Tolerance and Mortality:Comparison Of WHO and American Diabetes Association Diagnostic Criteria.The DECODE Study Group.European Diabetes Epidemiology Group.Diabetes Epidemiology:Collaborative Analysis of Diagnostic Criteria in Europe [J].Lancet,1999; 354(9 179):617-621.
  20. 20. ［19］DECODE Study Group,the European Diabetes Epidemiology Group.Glucose Tolerance and Cardiovascular Mortality:Comparison Of Fasting and 2-Hour Diagnostic Criteria[J].Arch Intern Med,2001; 161(3):397-405.
  21. 21. ［20］The DECODE Study Group.Is the Current Definition for Diabetes Relevant to Mortality Risk From All Causes and Cardiovascular and Noncardiovascular Diseases[J]? Diabetes Care,2003; 26（3）:637-687.
  22. 22. ［21］Surks MI,Ortiz E,Daniels GH,Sawin CT,Col NF Cobin RH,Franklyn JA,Hershman JM,Burman KD,Denke MA,Gorman C,Cooper RS,Weissman N.Subclinical Thyroid Disease:Scientific Review and Guidelines for Diagnosis and Management.[J].JAMA,2004,291:228-238.